Harvard Apparatus Regenerative Technology, Inc.

For the period ended Sep 30, 2025. Filed Nov 7, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 7, 2025

HRGNStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share and par value data)

	September 30,	December 31,
	2025	2024
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$1,319	$2,486
Accounts receivable	3	231
Inventory	22	80
Prepaid research and development	53	90
Prepaid expenses and other current assets	230	347
Total current assets	1,627	3,234
Property, plant and equipment, net	7	11
Right-of-use assets, net	221	293
Long-term prepaid contracts	691	904
Total assets	$2,546	$4,442
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$313	$452
Accrued and other current liabilities	327	221
Deferred revenue	128	—
Insurance premium financing payable	—	253
Operating lease liability	108	95
Total current liabilities	876	1,021
Operating lease liability, net of current portion	116	199
Total liabilities	992	1,220
Commitments and contingencies (Note 6)
Stockholders’ equity:
Common stock, par value $0.01 per share, 60,000,000 shares authorized; 17,168,979 and 15,918,979 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively	172	159
Additional paid-in capital	106,261	102,757
Accumulated deficit	(104,870)	(99,688)
Accumulated other comprehensive loss	(9)	(6)
Total stockholders’ equity	1,554	3,222
Total liabilities and stockholders’ equity	$2,546	$4,442

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.